Stay updated on Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page.

Latest updates to the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page
- Check4 days agoChange DetectedAdded September 2025 release notes (Revision: v3.0.2) and removed August 2025 notes (Revision: v3.0.1) plus the Back to Top link.SummaryDifference0.4%
- Check11 days agoChange DetectedThe page has been updated to reflect a new version, v3.0.1, indicating a recent revision. The previous version, v3.0.0, has been removed from the page.SummaryDifference0.1%
- Check18 days agoChange DetectedThe webpage has been updated to include new facility names and locations, as well as additional drug information for Lenvatinib and Pembrolizumab. Some outdated information has been removed, including previous location details and older drug information.SummaryDifference12%
- Check25 days agoNo Change Detected
- Check33 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.0%
- Check40 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.0%
- Check47 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.6%
Stay in the know with updates to Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page.